{"drugs":["Denosumab","Prolia","Xgeva"],"mono":{"0":{"id":"929634-s-0","title":"Generic Names","mono":"Denosumab"},"1":{"id":"929634-s-1","title":"Dosing and Indications","sub":[{"id":"929634-s-1-4","title":"Adult Dosing","mono":"<ul><li>correct hypocalcemia prior to initiation of therapy<\/li><li><b>Bone metastasis, Associated with Solid Tumors - Disorder of skeletal system; Prophylaxis:<\/b> (Xgeva(R)) 120 mg SUBQ every 4 weeks<\/li><li><b>Breast cancer - Osteopenia, In women at high risk of fracture receiving aromatase inhibitor therapy:<\/b> (Prolia(R)) 60 mg subQ once every 6 months plus calcium 1000 mg ORALLY once daily and at least 400 international units vitamin D ORALLY once daily<\/li><li><b>Giant cell tumor of bone, Unresectable or where surgical resection is likely to result in severe morbidity:<\/b> (Xgeva(R)) 120 mg SUBQ every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy<\/li><li><b>Hypercalcemia of malignancy, Refractory to bisphosphonates:<\/b> 120 mg SUBQ every 4 weeks, with additional 120-mg doses on days 8 and 15 of first month of therapy<\/li><li><b>Osteopenia, In men at high risk of fracture receiving androgen deprivation therapy - Prostate cancer, Nonmetastatic:<\/b> (Prolia(R)) 60 mg subQ once every 6 months plus calcium 1000 mg ORALLY once daily and at least 400 international units vitamin D ORALLY once daily<\/li><li><b>Osteoporosis, Male:<\/b> (Prolia(R)) 60 mg subQ once every 6 months plus calcium 1000 mg ORALLY once daily and at least 400 international units vitamin D ORALLY once daily<\/li><li><b>Postmenopausal osteoporosis:<\/b> (Prolia(R)) 60 mg subQ once every 6 months plus calcium 1000 mg ORALLY once daily and at least 400 international units vitamin D ORALLY once daily<\/li><li><b>Postmenopausal osteoporosis; Prophylaxis:<\/b> 60 mg SUBQ every 6 months has been used in a clinical trial (n=332)<\/li><\/ul>"},{"id":"929634-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>correct hypocalcemia prior to initiation of therapy (Xgeva(R))<\/li><li>Prolia(R), safety and effectiveness not established in pediatric patients<\/li><li>Xgeva(R), safety and effectiveness not established in pediatric patients, except in skeletally mature adolescents with giant cell tumor of bone<\/li><li><b>Giant cell tumor of bone, Unresectable or where surgical resection is likely to result in severe morbidity:<\/b> (Xgeva(R)) skeletally mature adolescents, 120 mg SUBQ every 4 weeks with additional 120 mg doses on days 8 and 15 of the first month of therapy<\/li><\/ul>"},{"id":"929634-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> no dose adjustments needed "},{"id":"929634-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bone metastasis, Associated with Solid Tumors - Disorder of skeletal system; Prophylaxis<\/li><li>Breast cancer - Osteopenia, In women at high risk of fracture receiving aromatase inhibitor therapy<\/li><li>Giant cell tumor of bone, Unresectable or where surgical resection is likely to result in severe morbidity<\/li><li>Hypercalcemia of malignancy, Refractory to bisphosphonates<\/li><li>Osteopenia, In men at high risk of fracture receiving androgen deprivation therapy - Prostate cancer, Nonmetastatic<\/li><li>Osteoporosis, Male<\/li><li>Postmenopausal osteoporosis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Postmenopausal osteoporosis; Prophylaxis<br\/>"}]},"3":{"id":"929634-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929634-s-3-9","title":"Contraindications","mono":"<ul><li>Hypersensitivity to any component of the product<\/li><li>Hypocalcemia; correct before initiating therapy<\/li><li>Pregnancy; may cause fetal harm<\/li><\/ul>"},{"id":"929634-s-3-10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- Skin reactions, including dermatitis, eczema, and rashes, have been reported; discontinuation may be warranted<\/li><li>Endocrine and Metabolic:<\/li><li>-- New or worsening hypocalcemia has been reported, with an increased risk in patients predisposed to hypocalcemia (eg, hypoparathyroidism, CrCl less than 30 mL\/min, dialysis, malabsorption syndromes); monitoring recommended<\/li><li>Immunologic:<\/li><li>-- Clinically significant hypersensitivity reactions, including anaphylaxis, have been reported; discontinue if occurs<\/li><li>-- Serious infections may occur, with an increased risk in immunosuppressed patients; consider discontinuation<\/li><li>Musculoskeletal:<\/li><li>-- Osteonecrosis of the jaw has been reported, with an increased risk with invasive dental procedures, concomitant therapies (eg, chemotherapy, corticosteroids, angiogenesis inhibitors, immunosuppressive therapy), and comorbid conditions (eg, infection, anemia, coagulopathy, diabetes, gingival infections); consider therapy interruption if invasive dental procedures are performed<\/li><li>-- Atypical low-energy or low-trauma fractures of the femur have been reported; interruption of therapy may be warranted<\/li><li>-- Severe and sometimes incapacitating musculoskeletal pain has been reported; consider discontinuation if occurs<\/li><li>-- Bone remodeling suppression has been reported in postmenopausal women with osteoporosis; monitoring recommended<\/li><li>-- Avoid use in pediatric patients; may impair bone growth in children with open growth plates and inhibit dentition eruption<\/li><\/ul>"},{"id":"929634-s-3-11","title":"Pregnancy Category","mono":"<ul><li>X (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"929634-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929634-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypercholesterolemia (Osteoporosis, 7.2%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (Bone metastases or hypercalcemia of malignancy, 20% to 21%), Nausea (Bone metastases, bone loss, giant cell tumor of bone, hypercalcemia of malignancy, 8.6% to 31%), Vomiting (15% to 24%)<\/li><li><b>Hematologic:<\/b>Anemia (Hypercalcemia of malignancy, 21%; osteoporosis, 3.3%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (6.7% to 14.3%), Backache (8.3%% to 34.7%), Pain in limb (9.9% to 11.7%)<\/li><li><b>Neurologic:<\/b>Asthenia (2.3% to 20%), Headache (Bone metastases or hypercalcemia of malignancy, 11% to 24%)<\/li><li><b>Renal:<\/b>Cystitis (5.9%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (6.7%), Upper respiratory infection (4.9%)<\/li><li><b>Other:<\/b>Fatigue (11% to 25%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Endocarditis<\/li><li><b>Dermatologic:<\/b>Cellulitis, Dermatitis, Erysipelas, Rash (2.5% to 5.1%)<\/li><li><b>Endocrine metabolic:<\/b>Hypocalcemia (Bone loss, bone metastases, giant cell tumor of bone, or osteoporosis, 1.7% to 18%), Hypophosphatemia (Bone metastases (any), 32%; hypercalcemia of malignancy (any), 76%; bone metastases or giant cell tumor of bone (severe), 9.5% to 15.4%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis (0.2% to 0.8%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction, Infectious disease, Serious (Hypercalcemia of malignancy, 6%; osteoporosis, 4%)<\/li><li><b>Musculoskeletal:<\/b>Aseptic necrosis of bone of jaw (up to 1.8%), Fracture of femur, Atypical<\/li><li><b>Respiratory:<\/b>Dyspnea (Bone metastases or hypercalcemia of malignancy, 21% to 27%)<\/li><li><b>Other:<\/b>Cancer (1.9% to 4.8%)<\/li><\/ul>"},"6":{"id":"929634-s-6","title":"Drug Name Info","sub":{"0":{"id":"929634-s-6-17","title":"US Trade Names","mono":"<ul><li>Prolia<\/li><li>Xgeva<\/li><\/ul>"},"2":{"id":"929634-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"929634-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929634-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929634-s-7","title":"Mechanism Of Action","mono":"Denosumab is a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor. Binding to the transmembrane or soluble protein RANKL inhibits the formation, function, and survival of osteoclasts resulting in decreased bone resorption and increased bone mass and strength. It also prevents RANKL from activating the RANK receptor on the surface of osteoclast-like giant cells.<br\/>"},"8":{"id":"929634-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929634-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 10 days<\/li><li>Bioavailability, SubQ: 62%<\/li><\/ul>"},"4":{"id":"929634-s-8-27","title":"Elimination Half Life","mono":"25.4 to 28 days  to 28 days <br\/>"}}},"9":{"id":"929634-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For subQ use only; do not administer IV, IM, or intradermally.<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>remove from the refrigerator and bring solution to room temperature by standing in the original container, usually 15 to 30 minutes; do not warm<\/li><li>solution should be clear, colorless to pale yellow and may contain trace amounts of translucent to white proteinaceous particles; do not use discolored solution or if many particles or foreign particulate matter is present<\/li><li>inject in the upper arm, upper thigh, or abdomen<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929634-s-10","title":"Monitoring","mono":"<ul><li>Bone metastasis from solid tumors: Prevention of skeletal-related events (pathological fracture, radiation therapy to bone, surgery to bone, or spinal cord compression) is indicative of efficacy<\/li><li>Giant cell tumor of bone: Evidence of tumor response may indicate efficacy<\/li><li>Osteoporosis: Reduction in the incidence of vertebral, nonvertebral, and hip fractures is indicative of efficacy<\/li><li>Serum calcium throughout therapy, especially in the first few weeks, phosphorus, and magnesium levels; within 14 days of injection; additional monitoring may be required with persistent hypocalcemia or severe renal impairment<\/li><li>Calcium and vitamin D intake<\/li><li>Routine oral exam; prior to treatment initiation<\/li><li>Dental examination with appropriate preventive dentistry, in patients with risk factors for osteonecrosis of the jaw.<\/li><li>Signs and symptoms of bone turnover suppression, such as osteonecrosis of the jaw, atypical fractures, and delayed fracture healing<\/li><\/ul>"},"11":{"id":"929634-s-11","title":"How Supplied","mono":"<ul><li><b>Prolia<\/b><br\/>Subcutaneous Solution: 60 MG\/ML<br\/><\/li><li><b>Xgeva<\/b><br\/>Subcutaneous Solution: 120 MG\/1.7 ML<br\/><\/li><\/ul>"},"13":{"id":"929634-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to notify the dentist of medication use prior to dental procedures.<\/li><li>Xgeva(R): Instruct female patients with reproductive potential to use effective contraception to avoid pregnancy during therapy and for 5 months after the last dose.<\/li><li>Prolia (R) side effects may include constipation, pain in extremity, back pain, hypercholesterolemia, musculoskeletal pain, and cystitis.<\/li><li>Xgeva(R) side effects may include dyspnea, arthralgia, fatigue\/asthenia, hypophosphatemia, and nausea.<\/li><li>Advise patient to immediately report symptoms of hypocalcemia or osteonecrosis of the jaw (eg, numbness, gum loss, or pain, swelling, or infection of jaw\/gums).<\/li><li>Counsel patient to immediately report symptoms of atypical femoral fracture (eg, new or unusual thigh, hip, or groin pain).<\/li><li>Prolia(R): Instruct patient to immediately report symptoms of pancreatitis, infection (including cellulitis), or dermatologic reaction (eg, dermatitis, rash, eczema).<\/li><li>Tell patient to immediately report symptoms of hypersensitivity reaction (ie, respiratory tract edema, dyspnea, lip swelling, pruritus, urticaria, rash).<\/li><li>Advise patient to take supplemental calcium and vitamin D as required to maintain adequate serum calcium levels during therapy.<\/li><\/ul>"}}}